Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

Author(s):
Luin, M. van; Ende, M.E. van der; Richter, C.; Visser, M.; Faraj, D.; Ven, A. van der; Gelinck, L.; Kroon, F.; Wit, F.W.; Schaik, R.H.N. van; Kuks, P.F.M.; Burger, D.M.
Published
2010
Publication type
Article / Letter to editor

Abstract

HIV-infected travellers frequently use atovaquone/ proguanil as malaria prophylaxis. We compared atovaquone/ proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)(0 -> t) for atovaquone relative to the healthy volunteers was 0.25 (0.16-0.38), 0.26 (0.17-0.41) and 0.54 (0.350.83) for patients on efavirenz, lopinavir/ ritonavir and atazanavir/ ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38-43%). Physicians should be alert for atovaquone/ proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ ritonavir or atazanavir/ ritonavir.

healthy-volunteers pharmacokinetics lamotrigine proguanil
Date issued
2010-05-15
Language
English
Is part of
AIDS (2010), Vol. 24, no. 8, p. 1223-1226
hdl
1887/109820